Kidney Cancer, Version 3.2015

Motzer, Robert J.; Jonasch, Eric; Agarwal, Neeraj; Beard, Clair J.; Bhayani, Sam B.; Bolger, Graeme B.; Chang, Sam S.; Choueiri, Toni K.; Costello, Brian A.; Derweesh, Ithaar; Gupta, Shilpa; Hancock, Steven; Kim, Jaeyeon; Kuzel, Timothy M.; Lam, Elaine T.; Lau, Clayton; Levine, Ellis G.; Lin, Daniel W.; Michaelson, M. Dror; Olencki, Thomas; Пили, Роберто; Plimack, Elizabeth R.; Rampersaud, Edward N.; Redman, Bruce G.; Ryan, Charles J.; Sheinfeld, Joel; Shuch, Brian; Sircar, Kanishka; Somer, Brad; Wilder, Richard B.; Dwyer, Mary A.

doi:10.6004/jnccn.2015.0022

Cited by 206 publications

(122 citation statements)

References 12 publications

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…[9][10][11] In the United States, pazopanib (VOTRIENT, GlaxoSmithKline) 12 and sunitinib (SUTENT, Pfizer) 13 are approved by the U.S. Food and Drug Administration and are among the choices for first-line treatment of advanced RCC based on demonstrated improvement in progression-free survival (PFS). 14 Pazopanib is an oral, once-daily therapy and was approved in 2009. 12 The efficacy and safety of pazopanib has been demonstrated in a randomized, double-blind, placebo-controlled, phase III trial.…”

Section: Study Sample Selectionmentioning

confidence: 99%

Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis

Byfield¹,

McPheeters²,

Burton³

et al. 2015

JMCP

View full text Add to dashboard Cite

BACKGROUND: For first-line therapy options for advanced renal cell carcinoma (RCC), clinical trials have demonstrated similar efficacy for pazopanib and sunitinib as well as differing side-effect profiles, which may affect patient persistence in self-administration of these oral medications. However, the treatment patterns of each drug in real-world clinical practice, as opposed to the controlled environment of a trial, have not been directly compared.

show abstract

Section: Study Sample Selectionmentioning

confidence: 99%

Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis

Byfield¹,

McPheeters²,

Burton³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

“…Based largely on such clinical trial evidence, NCCN guidelines recommend the use of everolimus and axitinib after failure with first TKI with category 1 recommendation. 17 Although head-to-head randomized comparisons are not available for all pairs of second targeted therapies, indirect comparisons of trial data have shown similar effectiveness for everolimus and axitinib. 28 In addition, in the case of the mTOR inhibitors everolimus and temsirolimus, a MOA different from that of a previous TKI also played a considerable role in treatment decisions.…”

Section: Discussionmentioning

confidence: 99%

“…10,16 Current NCCN guidelines recommend the use of VEGFR TKIs as first targeted therapy in patients with good-to-intermediate prognosis and the use of temsirolimus in patients with poor prognosis. 16,17 After failure of a first TKI, NCCN guidelines recommend using either another TKI, such as axitinib, or switching to a different MOA with everolimus. [16][17][18] Phase III trials, such as the AXIS trial comparing axitinib with sorafenib 15 and the RECORD-1 trial comparing everolimus with a placebo, have shown the efficacy of these treatments as second targeted therapies.…”

mentioning

confidence: 99%

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA

Pal

Signorovitch

et al. 2017

Int J of Urology

View full text Add to dashboard Cite

Objectives: To assess real-world treatment patterns of targeted therapies after failure of first-line tyrosine kinase inhibitors in patients with advanced renal cell carcinoma. Methods: A large, retrospective review of medical charts of patients with advanced renal cell carcinoma in the USA was carried out. Descriptive statistics were used to summarize physicians' and patients' characteristics, treatment sequences, and reasons for treatment choices. P-values were calculated using v 2 -tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. A descriptive comparison was carried out between current results and those of a previous treatment pattern study conducted in 2012 to identify changes in treatment patterns over time. Results: Sunitinib and everolimus remained the most commonly-used first and second targeted therapies, respectively. Among patients who continued to a third targeted therapy, everolimus and axitinib were the most commonly-used treatments after second targeted therapy with a tyrosine kinase inhibitor and a mammalian target of rapamycin inhibitor, respectively. The use of pazopanib as first targeted therapy, and of axitinib and sorafenib as second targeted therapies, increased over time. Efficacy, treatment guidelines and a different mechanism of action were the main reasons given by physicians for choosing among second targeted therapies after failure of a first tyrosine kinase inhibitor. Conclusions:The results of the present study document patterns of care during a period of rapid and ongoing therapeutic advancement in advanced renal cell carcinoma. Sequencing of therapies warrants ongoing analysis in light of new agents entering the advanced renal cell carcinoma treatment landscape.

show abstract

“…Bu tümörlerin %90'ı histopatolojik olarak berrak hücreli tiptir ve en sık akciğerlere metastaz yaptıkları bildirilmiştir (4). Güncel rehberlerde, şüpheli böbrek kitlesi saptanan hastalarda, öncelikle akciğer grafisi, metastaz açısından şüpheli bir bulgu saptanması halinde ise bilgisayarlı tomografi ile toraks görüntülemesi yapılması önerilmektedir (5,6). Bunun yanı sıra, küçük böbrek kitlelerinde metastatik potansiyelin düşük olması ve bundan dolayı hastalarda tanıya yönelik ileri toraks görüntülemesinin ve girişimlerinin gereksiz olabileceği bildirilmiştir (7).…”

Section: Introductionunclassified

Should We Perform Thoracic Imaging for Every Patient with a Renal Mass?

Şahan¹,

Garayev²,

Akgül³

et al. 2016

uob

View full text Add to dashboard Cite

Renal Kitle ile Başvuran Her Hastaya Toraks Görüntülemesi Yapmamız Gerekli mi?Objective: Current guidelines for the management of renal mass recommend thoracic imaging for potential metastatic nodules. Small size of the renal mass can be associated with low metastatic potential, which might question the necessity of thoracic imaging in this patient population. This study sought to evaluate the association of thoracic imaging findings with the renal mass characteristics in patients with pathologically proven renal cell carcinoma (RCC). Materials and Methods:We performed a retrospective analysis of patients with RCC, who underwent radical/partial nephrectomy and had baseline thoracic imaging available for review. Patients with a suspicious pulmonary mass were evaluated by the Department of Thoracic Surgery. Presence of lung nodule(s) and metastasis was determined and compared with patient and renal mass characteristics. Results: A total of 215 patients were included in the study. Pulmonary nodules suspicious for malignancy were present in 26.8% of the cases and 42% of these patients underwent further examination for the presence of a pulmonary mass. Pathological examination of the pulmonary nodule revealed RCC metastasis in 80% of patients who underwent biopsy or excision of the pulmonary nodule. Of note, in the subgroup analysis according to the pathological stage of the renal mass, 19.3% of patients with pT1a disease had a suspicious pulmonary mass on thoracic imaging. Of these patients, 25% underwent further examination of the pulmonary nodule with a RCC metastasis in 66.6%. Conclusion:The presence of suspicious lung nodules in patients with RCC has metastatic potential regardless of the size of the renal mass. These findings underscore the importance of baseline thoracic imaging and vigilant further evaluation of patients in whom pulmonary nodules are identified. Keywords: Renal cell carcinoma, pulmonary metastasis, renal mass, thoracic imaging Amaç: Renal kitle ile başvuran hastalarda akciğerlerin olası metastazlar açısından görüntülenmesi önerilmektedir. Renal kitlelerin küçük boyutlarda saptanmaları düşük metastatik potansiyele sahip olduklarını düşündürebilir ve bu nedenle toraks görüntülemesinin gerekliliği bu hasta grubunda tartışma konusu olabilir. Bu çalışmamızda renal kitle nedeniyle opere edilen ve patolojisi renal hücreli karsinom (RHK) olarak rapor edilen hastalarda, toraks görüntülemesi bulgularının renal kitle özellikleri ile ilişkisini araştırdık. Gereç ve Yöntem: Çalışmamızda kliniğimizde uygulanan radikal/parsiyel nefrektomi ameliyatı patolojisi RHK olarak rapor edilen ve ameliyat öncesi toraks görüntülemesi yapılmış hastalar retrospektif olarak değerlendirildi. Akciğerde şüpheli kitle saptanan hastalar göğüs cerrahisi bölümü tarafından değerlendirildi ve metastaz olduğu düşünülen lezyonlarından örnekleme yapıldı. Renal kitleye ait patolojik incelemede rapor edilen bulgular ile akciğerdeki şüpheli kitle ve metastaz saptanma oranları karşılaştırıldı. Bulgular: RHK tanı alan 215 hastadan %26,8'i...

show abstract

Kidney Cancer, Version 3.2015

Cited by 206 publications

References 12 publications

Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis

Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA

Should We Perform Thoracic Imaging for Every Patient with a Renal Mass?

Contact Info

Product

Resources

About